Conor Medsystems Issues Notice Pursuant to NASDAQ Marketplace Rule 4803(a)
February 15 2006 - 4:02PM
PR Newswire (US)
MENLO PARK, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Conor
Medsystems, Inc. (NASDAQ:CONR) today announced that on February 13,
2006, it received a letter from the NASDAQ Listing Qualifications
Department indicating that the Company had remedied its previous
non-compliance with the audit committee composition requirements
set forth in NASDAQ Marketplace Rule 4350(d) with the appointment
of Steven Gerber to the Audit Committee on February 10, 2006. The
Company was not in compliance with this rule for three days as a
result of the resignation of George Milne from the Board of
Directors on February 6, 2006. NASDAQ indicated in its letter that
the Company is now in compliance with Marketplace Rule 4350(d), and
with the issuance of this press release the matter is now closed.
About Conor Medsystems Conor Medsystems, Inc. develops innovative
controlled vascular drug delivery technologies, and has initially
focused on the development of drug-eluting stents to treat coronary
artery disease. For further information on Conor Medsystems and
controlled vascular delivery, visit http://www.conormed.com/.
DATASOURCE: Conor Medsystems, Inc. CONTACT: Michael Boennighausen,
Chief Financial Officer of Conor Medsystems, Inc., +1-650-614-4100
Web site: http://www.conormed.com/
Copyright
Conor Medsystems (NASDAQ:CONR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conor Medsystems (NASDAQ:CONR)
Historical Stock Chart
From Jul 2023 to Jul 2024